(Total Views: 776)
Posted On: 11/13/2020 9:09:12 PM
Post# of 145880
I wouldn’t put them in the same category as (end point mortality in Leronlimab)because #1 there endpoint is (“recovery faster”)much like Remdmesivirs endpoint. #2 only treat a very small fraction of the population of covid-19 severe/critical there trail has many exclusions and also lenzulimab can’t be administered through a shot like leronlimab. Def not comparing apples to apples here.
![](/m/images/thumb-up.png)
![](/m/images/thumb-down.png)